BUZZ - Vaxcyte shares fall after launching 1.1 billions stock and convertible bond offering
路透社2026/10/06 13:02On October 6 - Vaccine developer Vaxcyte (PCVX.O) shares fell 1.7% pre-market to $72.60, as the company seeks financing. PCVX launched a public offering on Monday night, including $500 millions in stock and pre-funded warrants, as well as $500 millions in convertible bonds (CBs) due October 15, 2032. On Monday, the PCVX share price soared approximately 31% and closed at $73.82 after the company announced its pneumonia vaccine VAX-31 met all primary endpoints in a late-stage clinical trial, generating immune responses at least comparable to Pfizer’s Prevnar 20 and Merck’s Capvaxive. The company plans to use the net proceeds from both offerings to fund the clinical development of VAX-31’s adult and pediatric programs—including the ongoing phase III adult study for VAX-31—clinical trials for its seasonal flu vaccine (OPUS-2), and other purposes. Jefferies, Leerink, BofA, Evercore, Goldman Sachs, and Guggenheim are joint book-running managers for this equity offering; Jefferies, Leerink, BofA, Goldman Sachs, and Evercore are joint lead underwriters for the convertible bonds. Based in San Carlos, California, PCVX has about 148.8 million shares outstanding and a market capitalization of $11 billions. As of Monday, the stock was up 60% year-to-date. According to London Stock Exchange Group (LSEG) data, out of 10 analysts, 9 rate the stock as “strong buy” or “buy” and 1 as “hold”; the median price target is $122. (For the convenience of non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or not capture the intended context, Reuters does not guarantee the accuracy of the automated text, which is provided for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
October 6 - ** Vaccine developer Vaxcyte (PCVX.O) shares fell 1.7% premarket to $72.60 as the company seeks to raise funds
** On Monday evening, PCVX launched a public offering (link) including $500 million in shares and pre-funded warrants, as well as $500 million in convertible bonds (CBs) maturing on October 15, 2032
** On Monday, PCVX stock soared about 31%, closing at $73.82 after the company announced that its pneumonia vaccine VAX-31 met all primary endpoints in late-stage clinical trials (link), producing immune responses at least comparable to Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive
** The company plans to use the net proceeds from both offerings to fund clinical development of the adult and pediatric VAX-31 programs, including the ongoing adult phase III trial of VAX-31, clinical trials for its seasonal flu vaccine (OPUS-2), and for other purposes
** Jefferies, Leerink, BofA, Evercore, Goldman Sachs, and Guggenheim are joint bookrunners for the equity offering; Jefferies, Leerink, BofA, Goldman Sachs, and Evercore are lead underwriters for the convertible bond offering
** California-based PCVX, headquartered in San Carlos, has about 148.8 million shares outstanding and a market capitalization of $11 billion
** As of Monday, the stock is up 60% for the year
** According to London Stock Exchange Group (LSEG) data, 9 out of 10 analysts rate the stock as “strong buy” or “buy,” with 1 rating it “hold”; the median price target is $122
(To assist non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may contain errors or omit necessary context; Reuters does not guarantee the accuracy of automated translations and provides them solely for readers’ convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Australia's Kelsian shares rise as asset sale triggers Morningstar's cautious optimism
Latest developments on October 7th – Kelsian Group (KLS.AX) shares briefly rose 1% to A$3.93 before narrowing gains to 0.3% by midday in Sydney. Morningstar holds a positive view on the transport operator’s recently announced A$150 million (US$104.76 million) sale of travel assets in mid-September. The investment research firm noted that this divestment relieves the transportation and travel operator from reliance on discretionary-spending businesses such as resorts, cruises, and tours. It also stated that the sale enables management to focus more on core operations and moderately reduces capital intensity. However, Morningstar pointed out that the sale means profits from the marine segment will still be "discretionary in nature." It added that the sale will leave the company’s earnings mainly dependent on its US interstate coach business, which is characterized by short-term contracts without cost-adjustment mechanisms and serves highly volatile sectors such as technology, oil, and gas. Year to date, the share price is down 8.2%. (US$1 = A$1.4318) (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or may not completely reflect the required context; Reuters does not guarantee the accuracy of translated texts, which are provided solely for reader convenience. Reuters is not responsible for any harm or loss arising from the use of automatic translation.)

JPMorgan raises Gilead Sciences' target price to $170.
BUZZ - Australian winemaker Treasury Wine recovers early losses, Jefferies believes its troubles in the US are easing
October 7th - Treasury Wine Estates (TWE.AX) shares recovered a 1.8% loss in afternoon trading and were basically flat. Jefferies maintained a "Hold" rating on TWE and an AUD 6 target price, stating that although excess inventory and rising costs in the US market are limiting upside potential, TWE’s underperformance relative to the broader market has been narrowing. The brokerage expects a 1.2% increase in EBIT for fiscal year 2027 and notes that the US wine market is showing moderate growth in the higher price segment. Jefferies mentioned that the price segment below $20 still faces significant challenges and emphasized that low-priced wines continue to face pressure. The brokerage pointed out that competitor Constellation Brands’ (STZ.N) wine and spirits business saw organic sales increase by 17.2% in the second quarter, with sales to retailers up by 10.2%. TWE shares have risen 6.1% year-to-date. (For the convenience of non-English speakers, Reuters offers automated translations of its report into a number of other languages. Automated translation may contain errors or may not capture the intended context, and Reuters does not guarantee the accuracy of this text. It is provided only for convenience, and Reuters is not liable for any damage or loss caused by the use of automated translation.)

Bitcoin price falls below 84,000 dollars, oil prices and the US dollar rise
